We are live on ! Find out more
MNTA

Momenta Pharmaceuticals, Inc.
MNTA

Delisted

MNTA was delisted on the 30th of September, 2020.

148 hedge funds and large institutions have $536M invested in Momenta Pharmaceuticals, Inc. in 2014 Q2 according to their latest regulatory filings, with 25 funds opening new positions, 51 increasing their positions, 49 reducing their positions, and 35 closing their positions.

New
Increased
Maintained
Reduced
Closed

7% more capital invested

Capital invested by funds: $500M → $536M (+$36.2M)

4% more repeat investments, than reductions

Existing positions increased: 51 | Existing positions reduced: 49

6% less funds holding

Funds holding: 158148 (-10)

23% less call options, than puts

Call options by funds: $7.93M | Put options by funds: $10.3M

29% less first-time investments, than exits

New positions opened: 25 | Existing positions closed: 35

Holders
148
Holders Change
-10
Holders Change %
-6.33%
% of All Funds
4.25%
Holding in Top 10
Holding in Top 10 Change
Holding in Top 10 Change %
% of All Funds
New
25
Increased
51
Reduced
49
Closed
35
Calls
$7.93M
Puts
$10.3M
Net Calls
-$2.32M
Net Calls Change
-$4.17M

MNTA Hedge Fund Activity: Q2 2014 in Review

148 of the 3,479 institutional investors tracked by Wall St. Rank reported a position in Momenta Pharmaceuticals, Inc. (MNTA) for Q2 2014, worth a combined $536M — up 7.2% from $500M a quarter earlier.

Sellers outnumbered buyers: 35 funds closed out of MNTA and 25 opened new positions — a net loss of 10 holders — while 49 trimmed existing stakes and 51 added.

The largest buyer was North Tide Capital, opening a new position worth an estimated $29.5M. The largest seller was T. Rowe Price Associates, cutting an estimated $7.81M.

  • 148 institutional investors held Momenta Pharmaceuticals, Inc. (MNTA) as of Q2 2014, down from 158 in Q1 2014.
  • Funds reported $536M of Momenta Pharmaceuticals, Inc. stock for Q2 2014, up 7.2% quarter-over-quarter.
  • 25 funds opened new Momenta Pharmaceuticals, Inc. positions in Q2 2014 and 35 closed out, a net change of -10 holders.
  • The largest Momenta Pharmaceuticals, Inc. buyer in Q2 2014 was North Tide Capital, an estimated $29.5M added.
  • The largest Momenta Pharmaceuticals, Inc. seller in Q2 2014 was T. Rowe Price Associates, an estimated $7.81M sold.

Based on aggregated 13F filings for Q2 2014.